Skip to main content

Table 1 Summary of dysregulated circRNAs in TNBC

From: Regulatory mechanisms, functions, and clinical significance of CircRNAs in triple-negative breast cancer

CircRNAs

Location

Technique/cohort

Method

Sample type

Expression in tumor

Roles

Biomarkers

AUC

Survival

Functions

Mechanism

Gene symbol

Pathway

References

circGFRA1

cytoplasm

MDA-MB-231/PTX

qRT-PCR

MDA-MB-231/PTX

Up in MDA-MB-231/PTX

Oncogenic

Prediction of therapy response

NR

NR

Increase the resistance of TNBC cells to PTX

Sponge miR-361-5p

TLR4

NR

[50]

circRPPH1

cytoplasm

GSE101123/20 TNBC versus 20 N

qRT-PCR

TNBC tissues and cells

Up

Oncogenic

NR

NR

NR

Proliferation and metastasis

Sponge miR-556-5p

YAP1

NR

[60]

circSEPT9

cytoplasm

RNA-seq of 4 TNBC versus 4 N/60 TNBC versus 60 N/ 80 TNBC

qRT-PCR, ISH

TNBC tissues and cells

Up

Oncogenic

Diagnosis and prognosis

0.711

OS

Proliferation, metastasis, apoptosis, and autophagy

Sponge miR-637

LIF

NR

[49]

circLARP4

NR

283 BC versus 283 N 65 TNBC versus 65 N

qRT-PCR

TNBC tissues and cells

Down

Antitumor

Prediction of therapy response

NR

NR

Inhibit the resistance of TNBC cells to DOX

NR

NR

NR

[89]

circUSP42

NR

RNA-seq of TNBC versus adjacent tissues/30 TNBC versus 30 N

qRT-PCR

TNBC tissues

Down

Antitumor

Prognosis

NR

OS, DFS

NR

NR

NR

NR

[98]

circABCB10

NR

MDA-MB-231/PTX

qRT-PCR

MDA-MB-231/PTX

Up in MDA-MB-231/PTX

Oncogenic

Prediction of therapy response

NR

NR

Increase the resistance of TNBC cells to PTX

Sponge Let-7a-5p

DUSP7

NR

[95]

circCDYL

NR

BC versus N

qRT-PCR

BC tissues and TNBC cells

Down

Antitumor

NR

NR

NR

Proliferation, migration, and invasion

Sponge miR-190a-3p

TP53INP1

NR

[61]

circZEB1

NR

30 TNBC versus 30 N

RT-qPCR

TNBC tissue, cells

Up

Oncogenic

NR

NR

NR

Proliferation and apoptosis

Sponge miR-448

eEF2k

NR

[58]

circGNB1

cytoplasm

Microarray/222 TNBC

RT-qPCR

TNBC tissue, cells

Up

Oncogenic

Prognosis

NR

OS, DFS

Proliferation and metastasis

Sponge miR-141-5p

IGF1R

NR

[59]

hsa_circ_0131242

NR

Microarray of TNBC versus normal tissues/30 TNBC versus 30 N /120 TNBC

RT-qPCR

TNBC tissue, cells

Up

Oncogenic

Prognosis

NR

OS

Proliferation and metastasis

Sponge miR-2682

NR

NR

[79]

circEIF3M

cytoplasm

RNA-seq of 3 TNBC versus 3 N /20 TNBC versus 20 N

RT-qPCR

TNBC tissue, cells

Up

Oncogenic

NR

NR

NR

Proliferation, metastasis, cell cycle, and apoptosis

Sponge miR-33a

CCND1

NR

[62]

circHER2

cytoplasm

RNA-seq of 5 TNBC versus 5 N /59 TNBC versus 59 N

RT-qPCR

TNBC tissue, cells

Up

Oncogenic

Prognosis and prediction of therapy response

NR

OS

Proliferation and invasion, circHER2 expressing TNBC are sensitive to Pertuzumab

Encode a novel HER2 variant HER2– 103

HER2– 103

Promote EGFR/HER3 interaction and activation

[75]

circPGAP3

cytoplasm

86 TNBC versus 86 N

RT-qPCR

TNBC tissue, cells

Up

Oncogenic

Prognosis

NR

OS,DFS

Proliferation and metastasis

Sponge miR-330-3p

myc

NR

[64]

circUBE2D2

cytoplasm

66 TNBC versus 66 N

RT-qPCR

TNBC tissue, cells

Up

Oncogenic

Prognosis and prediction of therapy response

NR

OS

Proliferation and metastasis, increase the resistance of TNBC cells to DOX

Sponge miR‑512‑3p

CDCA3

NR

[63]

circRAD18

cytoplasm

Microarray of TNBC versus adjacent tissues/31 TNBC versus 31 N/126 TNBC

RT-qPCR

TNBC tissue, cells

Up

Oncogenic

Diagnosis and prognosis

0.752

OS

Proliferation, metastasis, and apoptosis

Sponge miR-208a/3164

IGF1 and FGF2

NR

[78]

hsa_circ_0005320

cytoplasm

RNA-seq of 4 TNBC versus 4 N/20 TNBC versus 20 N

RTFQ-PCR

TNBC tissue, cells

Up

Oncogenic

NR

NR

NR

proliferation, cell cycle, and apoptosis

NR

LIF、P-STAT3

activate LIF-STAT3 pathway

[80]

hsa_circ_069718

NR

Microarray of TNBC versus adjacent tissues/35 TNBC versus 35 N

RT-qPCR

TNBC tissue, cells

Up

Oncogenic

Prognosis

NR

OS

Proliferation and invasion

NR

β-catenin, c-myc, and cyclin D1

Activate Wnt/β-catenin pathway

[81]

circFBXW7

cytoplasm

473 TNBC

RT-qPCR

TNBC tissue, cells

Down

Antitumor

Prognosis

NR

OS, DFS

Proliferation and metastasis

Sponge miR-197-3p and encode the FBXW7-185aa protein

FBXW7

NR

[74]

circCDR1as

NR

MDA-MB-231/5-Fu

RT-qPCR

MDA-MB-231/5-Fu

Up

Oncogenic

Prediction of therapy response

NR

NR

Increase the resistance of TNBC cells to 5-FU

Sponge miR-7

NR

NR

[97]

circAGFG1

cytoplasm

RNA-seq of 4 TNBC versus 4 N/40 TNBC versus 40 N/80 TNBC

RT-qPCR, ISH

TNBC tissue, cells

Up

Oncogenic

Diagnosis and prognosis

0.767

OS

Proliferation, metastasis, cell cycle, and apoptosis

Sponge miR-195-5p

CCNE1

NR

[57]

hsa_circ_0058514

NR

RNA-seq of 4 TNBC versus 4 N/20 TNBC versus 20 N

RTFQ-PCR

TNBC tissue, cells

Up

Oncogenic

NR

NR

NR

Proliferation, metastasis, cell cycle, and apoptosis

NR

CCNE1 and CDK2

NR

[82]

circTADA2A-E6

cytoplasm

Microarray of 8 specimens (4 TNBC and 4 luminal A) versus 3 normal tissues/178 BC versus 16 N /115 TNBC

RT-qPCR

TNBC tissue, cells

Down

Antitumor

Diagnosis and prognosis

0.8554

OS, DFS

Proliferation and metastasis

Sponge miR-203a-3p

SOCS3

NR

[48]

circAHNAK1

cytoplasm

Microarrays/20 TNBC versus 20 N/136 TNBC

RT-qPCR

TNBC tissue, cells

Down

Antitumor

Diagnosis and prognosis

0.72

OS, DFS

Proliferation and metastasis

Sponge miR-421

RASA1

NR

[56]

circITCH

NR

275 BC versus 68 N/91 TNBC

RT-qPCR

TNBC tissue, cells

Down

Antitumor

Prognosis

NR

OS

Proliferation and metastasis

Sponge miR-214/ miR-17

ITCH

Inactivate the Wnt/β-catenin pathway

[52]

circTFCP2L1

cytoplasm

Microarray of 3 TNBC versus 3 N/32 TNBC versus 32 N

RT-qPCR

TNBC tissue, cells

Up

Oncogenic

Prognosis

NR

DFS

Proliferation and migration

Sponge miR-7

PAK1

NR

[55]

circKIF4A

cytoplasm

Microarray/240 TNBC

RT-qPCR

TNBC tissue, cells

Up

Oncogenic

Prognosis

NR

OS, DFS

Proliferation and metastasis

Sponge miR-375

KIF4A

NR

[51]

circAMOTL1

NR

MDA-MB-231/PTX

qRT-PCR

MDA-MB-231/PTX

Up in MDA-MB-231/PTX

Oncogenic

Prediction of therapy response

NR

NR

Increase the resistance of TNBC cells to PTX

NR

BCL2, BAX and BAK

AKT pathway,

[96]

circKDM4C

cytoplasm

MDA-MB-231/DOX

qRT-PCR

MDA-MB-231/DOX

Down MDA-MB-231/DOX

Antitumor

Prediction of therapy response

NR

NR

Decreased the resistance of TNBC cells to doxorubicin

Sponge miR-548p

PBLD

NR

[90]

circPLK1

cytoplasm

Microarray of four cell lines (MDA-MB-231, MDA-MB-468, BT549 versus MCF-10A)/57 TNBC versus 57 N/240 TNBC

RT-qPCR

TNBC tissue, cells

Up

Oncogenic

Prognosis

NR

OS, DFS

Proliferation and metastasis

Sponge miR-296-5p

PLK1

NR

[54]

circANKS1B

cytoplasm

RNA-seq of 3 TNBC versus 3 N/20 TNBC versus 20 N/ 165 BC versus 40 N

RT-qPCR

BC tissue, cells

Up

Oncogenic

Prognosis

NR

OS

Invasion and metastasis

Sponge miR-148a/ 152-3p

USF1

Activate of TGF-β1 signaling pathway

[47]

circUBAP2

cytoplasm

78 TNBC versus 78 N

RT-qPCR

TNBC tissue, cells

Up

Oncogenic

Prognosis

NR

OS

Proliferation, metastasis, and apoptosis

Sponge miR-661

MTA1

NR

[53]

circ-ciRS-7

cytoplasm

32 TNBC versus 32 N

RT-qPCR

TNBC tissue, cells

Up

Oncogenic

NR

NR

NR

Invasion and metastasis

Sponge miR-1299

MMPs

NR

[45]

circMTO1

nucleus

MDA-MB-231/monastrol

qRT-PCR

MDA-MB-231/monastrol

Down MDA-MB-231/ monastrol

Antitumor

Prediction of therapy response

NR

NR

Reverses the resistance of TNBC cells to monastrol

Binding to TRAF4

Eg5

NR

[67]

circEPSTI1

NR

Microarray of 3 TNBC versus 3 N/37 TNBC versus 30 N/240 TNBC

RT-qPCR, ISH

TNBC tissue, cells

Up

Oncogenic

Prognosis

NR

OS, DFS

Proliferation and apoptosis

SPONGE miR-4753/6809

BCL11A

NR

[46]

circGFRA1

cytoplasm

Microarray of TNBC cells and MCF-10A /51 TNBC versus 51 N/222 TNBC

RT-qPCR

TNBC tissue, cells

Up

Oncogenic

Prognosis

NR

OS, DFS

Proliferation and apoptosis

Sponge miR-34a

GFRA1

NR

[29]

hsa_circ_0006528

NR

MDA-MB-231/DOX

qRT-PCR

MDA-MB-231/DOX

Up in MDA-MB-231/DOX

Oncogenic

Prediction of therapy response

NR

NR

Increase the resistance of TNBC cells to PTX

Sponge miR-7–5p

Raf1

NR

[87]

  1. TNBC triple-negative breast cancer, N normal, DOX doxorubicin, PTX paclitaxel, 5-FU 5-fluorouracil, MDA-MB-231/PTX PTX-resistant MDA-MB-231, MDA-MB-231/DOX DOX-resistant MDA-MB-231, MDA-MB-231/ monastrol monastrol-resistant MDA-MB-23, 5-Fu-resistant MDA-MB-231 MDA-MB-231/5-FU, OS overall survival, DFS disease-free survival, AUC area under the curve, NR not report, ISH in situ hybridization, qRT-PCR quantitative real-time PC